Related Experiment Video
Updated: Jan 2, 2026
An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas
Published on: October 10, 2025
Funding community collaboration to develop effective therapies for neurofibromatosis type 1 tumors
Salvatore La Rosa1, Vidya Browder1, Annette C Bakker1
1Children's Tumor Foundation, New York, NY, USA.
Abstract:
The time from identifying a drug target to a new drug approval is often measured in decades and can take even longer for therapies to treat rare diseases. In fact, 95% of rare diseases do not have a specific therapy approved at all. Coordinated efforts to augment the drug development pipeline along with long-term and comprehensive support that enable scientific breakthroughs for rare diseases are possible, but it requires integration across multiple stakeholders. This article analyzes the coordinated funding efforts of four federal and philanthropic organizations to advance drug development for neurofibromatosis type 1-associated tumors and discusses how these organizations have been collaborating and evolved practices to optimize funding and research support.
Insights
Developing new drugs for rare diseases like neurofibromatosis type 1 (NF1) is slow. Coordinated funding and collaboration among stakeholders can accelerate drug development and support scientific breakthroughs for these conditions.
Area of Science:
- Drug development
- Rare diseases
- Oncology
Background:
- Drug development for rare diseases is lengthy, with 95% lacking approved therapies.
- Neurofibromatosis type 1 (NF1)-associated tumors represent a significant unmet medical need.
- Accelerating the drug pipeline requires integrated, long-term support.
Purpose of the Study:
- To analyze coordinated funding efforts for neurofibromatosis type 1 (NF1)-associated tumor drug development.
- To examine collaboration and evolving practices among federal and philanthropic organizations.
- To identify strategies for optimizing research funding and support for rare diseases.
Main Methods:
- Analysis of funding initiatives from four key federal and philanthropic organizations.
- Review of collaborative strategies and practice evolution in drug development.
- Case study focused on neurofibromatosis type 1 (NF1)-associated tumors.
Main Results:
- Identified successful integration models across multiple stakeholders in rare disease drug development.
- Documented collaborative practices that optimize funding and research support.
- Demonstrated the potential for accelerated therapeutic development through coordinated efforts.
Conclusions:
- Coordinated funding and stakeholder integration are crucial for advancing rare disease therapies.
- Collaborative models can overcome challenges in drug development for conditions like NF1.
- Optimized funding strategies can expedite scientific breakthroughs and improve patient outcomes.
More Related Videos
05:44Author Spotlight: Collecting the Brain and Serum from the Same Mice Fetus to Study Brain Tumor Development
Published on: May 17, 2024
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
